CDK9 and cancer: Further optimization of this novel scaffold was conducted by our team with the identification of 2-phenylimidazopyrazin-3-amine 2 as a CDK9 inhibitor with submicromolar IC50 values and a potent antiproliferative effect against a panel of cancer cell lines with single-digit IC50 [40].